HR positive	HER2 Negative Breast Cancer	HR positive	HER2 Negative Breast Cancer	sacituzumab govitecan-hziy Sensitive: A1 - Approval sacituzumab govitecan-hziy Sensitive : A1	sacituzumab govitecan-hziy Sensitive: A1 - Approval sacituzumab govitecan-hziy Sensitive : A1
HR positive	HER2 Negative Breast Cancer	HR positive	HER2 Negative Breast Cancer	palbociclib Sensitive: A1 - Approval palbociclib Sensitive : A1	palbociclib Sensitive: A1 - Approval palbociclib Sensitive : A1
HR positive	HER2 Negative Breast Cancer	HR positive	HER2 Negative Breast Cancer	ribociclib Sensitive: A1 - Approval ribociclib Sensitive : A1	ribociclib Sensitive: A1 - Approval ribociclib Sensitive : A1
PIK3CA mutation + HR positive	HER2 Negative Breast Cancer	PIK3CA mutation + HR positive	HER2 Negative Breast Cancer	alpelisib Sensitive: A1 - Approval alpelisib Sensitive : A1	alpelisib Sensitive: A1 - Approval alpelisib Sensitive : A1
HR positive	HER2 Negative Breast Cancer	HR positive	HER2 Negative Breast Cancer	abemaciclib Sensitive: A1 - Approval abemaciclib Sensitive : A1	abemaciclib Sensitive: A1 - Approval abemaciclib Sensitive : A1
HR positive	HER2 Negative Breast Cancer	HR positive	HER2 Negative Breast Cancer	everolimus Sensitive: A1 - Approval everolimus Sensitive : A1	everolimus Sensitive: A1 - Approval everolimus Sensitive : A1
BRCA2 mutation	HER2 Negative Breast Cancer	BRCA2 mutation	HER2 Negative Breast Cancer	talazoparib Sensitive: A1 - Approval talazoparib Sensitive : A1	talazoparib Sensitive: A1 - Approval talazoparib Sensitive : A1
BRCA1 mutation	HER2 Negative Breast Cancer	BRCA1 mutation	HER2 Negative Breast Cancer	talazoparib Sensitive: A1 - Approval talazoparib Sensitive : A1	talazoparib Sensitive: A1 - Approval talazoparib Sensitive : A1
PIK3CA mutation + HR positive	HER2 Negative Breast Cancer	PIK3CA mutation + HR positive	HER2 Negative Breast Cancer	palbociclib + inavolisib Sensitive: A1 - Approval palbociclib + inavolisib Sensitive : A1	palbociclib + inavolisib Sensitive: A1 - Approval palbociclib + inavolisib Sensitive : A1
BRCA1 mutation	HER2 Negative Breast Cancer	BRCA1 mutation	HER2 Negative Breast Cancer	olaparib Sensitive: A1 - Approval olaparib Sensitive : A1	olaparib Sensitive: A1 - Approval olaparib Sensitive : A1
BRCA2 mutation	HER2 Negative Breast Cancer	BRCA2 mutation	HER2 Negative Breast Cancer	olaparib Sensitive: A1 - Approval olaparib Sensitive : A1	olaparib Sensitive: A1 - Approval olaparib Sensitive : A1
PIK3CA mutation + ER positive	HER2 Negative Breast Cancer	PIK3CA mutation + ER positive	HER2 Negative Breast Cancer	capivasertib Sensitive: A1 - Approval capivasertib Sensitive : A1	capivasertib Sensitive: A1 - Approval capivasertib Sensitive : A1
HR positive	HER2 Negative Breast Cancer	HR positive	HER2 Negative Breast Cancer	fulvestrant Sensitive: A1 - Approval fulvestrant Sensitive : A1	fulvestrant Sensitive: A1 - Approval fulvestrant Sensitive : A1
ER positive + ESR1 mutation	HER2 Negative Breast Cancer	ER positive + ESR1 mutation	HER2 Negative Breast Cancer	elacestrant Sensitive: A1 - Approval elacestrant Sensitive : A1	elacestrant Sensitive: A1 - Approval elacestrant Sensitive : A1
HR positive	HER2 Negative Breast Cancer	HR positive	HER2 Negative Breast Cancer	capivasertib Sensitive: A1 - Approval capivasertib Sensitive : A1	capivasertib Sensitive: A1 - Approval capivasertib Sensitive : A1
AKT1 mutation + HR positive	HER2 Negative Breast Cancer	AKT1 mutation + HR positive	HER2 Negative Breast Cancer	capivasertib Sensitive: A1 - Approval capivasertib Sensitive : A1	capivasertib Sensitive: A1 - Approval capivasertib Sensitive : A1
PIK3CA mutation + HR positive	HER2 Negative Breast Cancer	PIK3CA mutation + HR positive	HER2 Negative Breast Cancer	capivasertib Sensitive: A1 - Approval capivasertib Sensitive : A1	capivasertib Sensitive: A1 - Approval capivasertib Sensitive : A1
PTEN mutation + HR positive	HER2 Negative Breast Cancer	PTEN mutation + HR positive	HER2 Negative Breast Cancer	capivasertib Sensitive: A1 - Approval capivasertib Sensitive : A1	capivasertib Sensitive: A1 - Approval capivasertib Sensitive : A1
PTEN deletion + ER positive	HER2 Negative Breast Cancer	PTEN deletion + ER positive	HER2 Negative Breast Cancer	capivasertib Sensitive: A1 - Approval capivasertib Sensitive : A1	capivasertib Sensitive: A1 - Approval capivasertib Sensitive : A1
AKT1 mutation + ER positive	HER2 Negative Breast Cancer	AKT1 mutation + ER positive	HER2 Negative Breast Cancer	capivasertib Sensitive: A1 - Approval capivasertib Sensitive : A1	capivasertib Sensitive: A1 - Approval capivasertib Sensitive : A1
HER-2 negative	HER2 Negative Breast Cancer	HER-2 negative	HER2 Negative Breast Cancer	Sensitive: A2 - Guideline Sensitive : A2	Sensitive: A2 - Guideline Sensitive : A2
HR negative + BRCA1 mutation	HER2 Negative Breast Cancer	HR negative + BRCA1 mutation	HER2 Negative Breast Cancer	olaparib Sensitive: A2 - Guideline olaparib Sensitive : A2	olaparib Sensitive: A2 - Guideline olaparib Sensitive : A2
HER-2 negative	HER2 Negative Breast Cancer	HER-2 negative	HER2 Negative Breast Cancer	eribulin mesylate Sensitive: A2 - Guideline eribulin mesylate Sensitive : A2	eribulin mesylate Sensitive: A2 - Guideline eribulin mesylate Sensitive : A2
ER positive	HER2 Negative Breast Cancer	ER positive	HER2 Negative Breast Cancer	letrozole Sensitive: A2 - Guideline letrozole Sensitive : A2	letrozole Sensitive: A2 - Guideline letrozole Sensitive : A2
BRCA2 mutation	HER2 Negative Breast Cancer	BRCA2 mutation	HER2 Negative Breast Cancer	PARP inhibitor Sensitive: A2 - Guideline PARP inhibitor Sensitive : A2	PARP inhibitor Sensitive: A2 - Guideline PARP inhibitor Sensitive : A2
BRCA1 mutation	HER2 Negative Breast Cancer	BRCA1 mutation	HER2 Negative Breast Cancer	PARP inhibitor Sensitive: A2 - Guideline PARP inhibitor Sensitive : A2	PARP inhibitor Sensitive: A2 - Guideline PARP inhibitor Sensitive : A2
HER-2 negative	HER2 Negative Breast Cancer	HER-2 negative	HER2 Negative Breast Cancer	ribociclib Sensitive: A2 - Guideline ribociclib Sensitive : A2	ribociclib Sensitive: A2 - Guideline ribociclib Sensitive : A2
HER-2 negative	HER2 Negative Breast Cancer	HER-2 negative	HER2 Negative Breast Cancer	docetaxel Sensitive: A2 - Guideline docetaxel Sensitive : A2	docetaxel Sensitive: A2 - Guideline docetaxel Sensitive : A2
HER-2 negative	HER2 Negative Breast Cancer	HER-2 negative	HER2 Negative Breast Cancer	paclitaxel Sensitive: A2 - Guideline paclitaxel Sensitive : A2	paclitaxel Sensitive: A2 - Guideline paclitaxel Sensitive : A2
HER-2 negative	HER2 Negative Breast Cancer	HER-2 negative	HER2 Negative Breast Cancer	bevacizumab Sensitive: A2 - Guideline bevacizumab Sensitive : A2	bevacizumab Sensitive: A2 - Guideline bevacizumab Sensitive : A2
HER-2 negative	HER2 Negative Breast Cancer	HER-2 negative	HER2 Negative Breast Cancer	albumin-bound paclitaxel Sensitive: A2 - Guideline albumin-bound paclitaxel Sensitive : A2	albumin-bound paclitaxel Sensitive: A2 - Guideline albumin-bound paclitaxel Sensitive : A2
HER-2 negative	HER2 Negative Breast Cancer	HER-2 negative	HER2 Negative Breast Cancer	ixabepilone Sensitive: A2 - Guideline ixabepilone Sensitive : A2	ixabepilone Sensitive: A2 - Guideline ixabepilone Sensitive : A2

HER2 Negative Breast Cancer

Associations(541)

Associations
(541)